Prostate Cancer Cell Phenotypes Remain Stable Following PDE5 Inhibition in the Clinically Relevant Range

Area of Science:

• Oncology
• Pharmacology
• Urology

Background:

• cGMP-specific phosphodiesterase 5 (PDE5) inhibitors are widely used for male reproductive health.
• Their use in prostate cancer patients post-surgery raises questions about effects on residual tumor cells.

Purpose of the Study:

• To investigate the impact of PDE5 inhibitors on prostate cancer cell proliferation, migration, and colony formation.
• To determine if PDE5 inhibitors have cancer-promoting or inhibiting effects on prostate cancer cells.

Main Methods:

• Prostate cancer cell lines were treated with PDE5 inhibitors at clinically relevant and supra-clinical concentrations.
• Cell proliferation, colony formation, and migration assays were performed.
• Cells were co-treated with a cGMP synthesis stimulator to assess combined effects.

Main Results:

• Clinically relevant concentrations of PDE5 inhibitors did not alter proliferation, colony formation, or migration.
• Co-treatment with a cGMP stimulator also showed no significant changes in these phenotypes.
• Supra-clinical concentrations of PDE5 inhibitors unexpectedly inhibited proliferation, colony formation, and migration.

Conclusions:

• PDE5 inhibitors appear safe as adjuvant agents for normal tissue recovery post-prostatectomy, supporting current clinical views.
• The study provides tumor cell-autonomous evidence against PDE5 inhibitors promoting cancer.
• Potential cancer-promoting effects in a complex tumor microenvironment cannot be entirely excluded.